Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic.
Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development.
Each one of us together for patients
We believe our modular approach to selecting our in vivo and ex vivo programs positions us to build a full-spectrum genome editing company, with a pipeline across a range of indications. This approach enables us to generate a wealth of data that opens the potential therapeutic applications of the CRISPR/Cas9 technology across a broad range of diseases.
$NTLA News: @MHRAgovuk approves protocol amendment to include patients with #ATTR amyloidosis with cardiomyopathy in Intellia’s ongoing Phase 1 study of NTLA-2001. More details here: https://t.co/7sO49vzNj2 #CRISPR #genomeediting https://t.co/28ii2rGGAA
Tomorrow, Intellia VP, Disease Biology, Sean Burns, M.D., will be speaking at the #CRISPR 2.0 Summit hosted by @HansonWade on the development of systemic CRISPR-based therapeutics. Learn more: https://t.co/KrvNBUtsR9 #genomeediting https://t.co/lQEAl30prx